ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Financial Statements and Exhibits
Item9.01 of Form8-K that were previously omitted from the
Original Report as permitted by Item9.01(a)(4). Except as
provided herein, the disclosures made in the Original Report
remain unchanged.
Item2.01.Completion of Acquisition or Disposition of
Assets.
to the terms and conditions of that certain Agreement and Plan of
Merger, dated as of April27, 2016, by and among Abbott, St.Jude
Medical,Inc., Vault Merger Sub,Inc. and Vault Merger Sub,LLC,
Abbott completed the acquisition of St.Jude Medical,Inc. (the
“Transaction”) on January4, 2017.
In connection with the Transaction, Abbott filed the Original
Report describing the acquisition. Abbott is now filing this
amendment to include the historical financial statements and pro
forma financial information required by Item9.01 of Form8-K.
Item9.01Financial Statements and Exhibits
(a)Financial Statements of Business Acquired
The audited St.Jude Medical,Inc. consolidated statements of
earnings, statements of comprehensive income, statements of
shareholders’ equity and statements of cash flows for three-year
period ended December31, 2016, the audited St.Jude Medical,Inc.
consolidated balance sheets as of December31, 2016 and January2,
2016, and the accompanying Notes to the Consolidated Financial
Statements are attached hereto as Exhibit99.1 and incorporated by
reference.
(b)Pro forma financial information
The following information is attached hereto as Exhibit99.2 and
incorporated herein by reference:
- (i)
-
Unaudited Pro Forma Condensed Combined Consolidated Balance
Sheet as of December31, 2016. - (ii)
-
Unaudited Pro Forma Condensed Combined Consolidated Statement
of Earnings for the year ended December31, 2016. - (iii)
-
Notes to the Unaudited Pro Forma Condensed Combined Financial
Information.
(d)Exhibits
| Exhibit No. | Exhibit | ||
|---|---|---|---|
| 23.1 |
Consent of Ernst YoungLLP, independent registered public accounting firm for St.Jude Medical,Inc. |
||
| 99.1 | Audited Financial Statements of St.Jude Medical,Inc. | ||
| 99.2 | Pro Forma Financial Information. | ||
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| ABBOTT LABORATORIES | ||||
|
Date: February21, 2017 |
By: |
/s/BRIAN B. YOOR Brian B. Yoor Executive Vice |
||
EXHIBIT INDEX
| Exhibit No. | Exhibit | ||
|---|---|---|---|
| 23.1 |
Consent of Ernst YoungLLP, independent registered public accounting firm for St.Jude Medical,Inc. |
||
| 99.1 | Audited Financial Statements of St.Jude Medical,Inc. | ||
| 99.2 | Pro Forma Financial Information. | ||
QuickLinks
Item 9.01 Financial Statements and Exhibits
About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. ABBOTT LABORATORIES (NYSE:ABT) Recent Trading Information
ABBOTT LABORATORIES (NYSE:ABT) closed its last trading session 00.00 at 44.69 with 9,632,008 shares trading hands.
